Efficacy of adalimumab in Korean patients with Crohn's disease

Gut and Liver

Volumn 10, Issue 2, 2016, Pages 255-261

  Sohn, Il Woong ^a   Kim, Sung Tae ^a   Kim, Bun ^a   Lee, Hyun Jung ^a   Park, Soo Jung ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a   Cheon, Jae Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adalimumab; Crohn disease; Remission induction; Treatment outcome

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE; ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HERPES ZOSTER; HUMAN; KOREAN (PEOPLE); MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONTREAL CLASSIFICATION; OUTCOME ASSESSMENT; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960491191     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15165     Document Type: Article

References (22)

1. Lee YW, Lee KM, Chung WC, Paik CN, Sung HJ, Oh YS. Clinical and endoscopic recurrence after surgical resection in patients with Crohn's disease. Intest Res 2014;12:117-123.
2. Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. World J Gastroenterol 2014;20:11525-11537.
3. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
4. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis. Am J Gastroenterol 2013;108:40-47.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-333.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65.
7. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-1239.
8. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med 2007;146:829-838.
9. Chang CW, Wei SC, Chou JW, et al. Safety and efficacy of adalimumab for patients with moderate to severe Crohn's disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study. Intest Res 2014;12:287-292.
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5A-36A.
11. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
12. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-698.
13. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: A systematic review and network metaanalysis. Mayo Clin Proc 2014;89:1621-1635.
14. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-1640.
15. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010;4:1-14.
16. Yang DH, Yang SK, Park SH, et al. Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. Gut Liver 2015;9:80-86.
17. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013;38:1236-1247.
18. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review. Am J Gastroenterol 2011;106:674-684.
19. Ferrante M, Karmiris K, Newnham E, et al. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. J Crohns Colitis 2012;6:116-131.
20. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-936.
21. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-653.
22. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-1224.